endothelin receptor antagonist

Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.

Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

by Pallavi Madhiraju
May 9, 2026
0 Comments

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More

Pharma & Biotech

Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?

by Soujanya Ravi
February 13, 2026
0 Comments

Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.

Read More